Sigma Of Australia Could Face $185 Million Class-Action Suit
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceuticals faces a possible $185 million suit by institutional investors over accounting and disclosure practices involved with the firm's financial problems